HealthQuill pfizer
Sixty percent of the patients treated with Pfizerā€™s Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression after five years, according to company data.
Drugs Health Pharma

Pfizer’s drug helps people with rare lung cancer live longer, data shows

Sixty percent of the patients treated with Pfizerā€™s Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression.

Read More
Pfizer Inc., announced a $1.5 billion ā€œmulti-yearā€ savings plan to cut costs of goods sold, on top of a similar $4 billion initiative unveiled in October last year, when sales of its Covid-19 vaccine plummeted.
Drugs Health Pharma

Pfizer Inc. unveils a new $1.5 billion plan to cut costs as vaccine sales fall

Pfizer Inc., announced a $1.5 billion ā€œmulti-yearā€ savings plan to cut costs of goods sold, on top of a similar $4 billion initiative.

Read More
Pfizer and AstraZeneca will invest about $1 billion separately in France to set up and expand facilities, Finance MinisterĀ Bruno Le Maire said, according to a publicly-funded television network, France 24.
Drugs Health Pharma

Pfizer, AstraZeneca to invest close to $1 billion in FranceĀ to expand

HQ Team May 13, 2024: Pfizer and AstraZeneca will invest about $1 billion separately in France to set up and expand facilities, Finance.

Read More
A young boy, treated for a rare genetic disease, died during a mid-stage clinical trial conducted by Pfizer, according to a statement posted by a non-profit group on its website quoting a company statement.
Drugs Health Pharma

Boy dies during Pfizerā€™s clinical trial probing rare genetic disease

HQ Team May 8, 2024: A young boy, treated for a rare genetic disease, died during a mid-stage clinical trial conducted by Pfizer,.

Read More
The US health regulator has approved Pfizerā€™s drug to treat cervical cancer patients whose disease has progressed beyond the chemotherapy stage.
Drugs Health Pharma

Pfizer gets full US regulatory approval for cervical cancer drug

HQ Team April 30, 2024: The US health regulator has approved Pfizerā€™s drug to treat cervical cancer patients whose disease has progressed beyond.

Read More
The European Commission has granted Pfizer Inc., marketing authorisation for a drug to treat adult patients with intra-abdominal infections, hospital-acquired pneumonia and complex urinary tract infections.
Drugs Health Pharma

EC marketing nod for Pfizer drug to fight antimicrobial resistance

HQ Team April 22, 2024: The European Commission has granted Pfizer Inc., marketing authorisation for a drug to treat adult patients with intra-abdominal.

Read More
Pfizer Inc., announced its experimental drug for treating a lower respiratory tract disease for adults between 18- to 59 years has met its primary goals in trials.
Drugs Health Pharma

Last-stage trials achieve ā€œpositiveā€ results for RSV drug: Pfizer says

HQ Team April 9, 2024: Pfizer Inc., announced its experimental drug for treating a lower respiratory tract disease for adults between 18- to.

Read More
Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded positive results and improved overall survival rates.
Drugs Health Pharma

Pfizer says trials on lymphoma drug ā€˜positive,ā€™ extends life of patientsĀ 

HQ Team March 12, 2024: Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded.

Read More
The FDA has approved Pfizerā€™s Besponsa drug for pediatric patients aged one year and above to treat acute leukaemia.
Drugs Health Pharma

Pfizerā€™s pediatric leukaemia drug gets regulator FDA’s green light

HQ Team March 7, 2024: The FDA has approved Pfizerā€™s Besponsa drug for pediatric patients aged one year and above to treat acute.

Read More
The Food and Drug Administration (FDA) has green-lighted Astellas Pharmaā€™s prostrate cancer drug Xtandi five weeks ahead of the scheduled approval date.
Drugs Health Pharma

Astellasā€™ prostate cancer drug for metastasis-free survival gets nod

HQ Team November 18, 2023: The Food and Drug Administration (FDA) has green-lighted Astellas Pharmaā€™s prostrate cancer drug Xtandi five weeks ahead of.

Read More